FUBP1 has been reported as a biomarker for nasopharyngeal carcinoma gliomas [36] and clear cell renal cell carcinoma [37], and previously described as a transcriptional regulator of the important proto-oncogene c-Myc[38], as well as a potential therapeutic target. This evidence concerns the gene MYC and central nervous system cancer.